schliessen

Filtern

 

Bibliotheken

Simultaneous delivery of doxorubicin and curcumin encapsulated in liposomes of pegylated RGDK-lipopeptide to tumor vasculature

Curcumin, because of its distinguishing ability to inhibit activation of transcription factor linked to chemoresistance and drug transporters, is now being co-administered with various potent anti-cancer drugs. In the present study, we report on such potentiating capabilities of curcumin in anti-ang... Full description

Journal Title: Biomaterials February 2014, Vol.35(5), pp.1643-1656
Main Author: Barui, Sugata
Other Authors: Saha, Soumen , Mondal, Goutam , Haseena, Shaik , Chaudhuri, Arabinda
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0142-9612 ; DOI: 10.1016/j.biomaterials.2013.10.074
Link: http://dx.doi.org/10.1016/j.biomaterials.2013.10.074
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: sciversesciencedirect_elsevierS0142-9612(13)01330-6
title: Simultaneous delivery of doxorubicin and curcumin encapsulated in liposomes of pegylated RGDK-lipopeptide to tumor vasculature
format: Article
creator:
  • Barui, Sugata
  • Saha, Soumen
  • Mondal, Goutam
  • Haseena, Shaik
  • Chaudhuri, Arabinda
subjects:
  • Pegylated Rgdk-Lipopeptide
  • Curcumin–Doxorubicin Synergy
  • Tumor Growth Inhibition
  • Targeting Tumor Vasculature
  • Anti-Angiogenic Chemotherapy
ispartof: Biomaterials, February 2014, Vol.35(5), pp.1643-1656
description: Curcumin, because of its distinguishing ability to inhibit activation of transcription factor linked to chemoresistance and drug transporters, is now being co-administered with various potent anti-cancer drugs. In the present study, we report on such potentiating capabilities of curcumin in anti-angiogenic cancer therapy. With a view to simultaneously deliver curcumin and doxorubicin to tumor vasculature in anti-angiogenic cancer therapy, herein we report on the design & synthesis of a tumor vasculature targeting pegylated RGDK-lipopeptide. We show that curcumin & doxorubicin co-encapsulated within the liposomes of the presently described pegylated RGDK-lipopeptide exhibit synergism in inhibiting proliferation, invasion and migration of both tumor and endothelial cells presumably by inhibiting proliferation and metastasis related genes both at mRNA & protein levels. Pronounced tumor growth inhibition was observed in mice treated with formulations containing both the drugs. Tumor growth inhibition was found to be 2–3 folds less in mice treated with formulations containing only curcumin or only doxorubicin. The presently described liposomal system is expected to find future use for simultaneously delivering potentially any combinations of hydrophilic and hydrophobic potent small molecule cancer therapeutics to tumor vasculature in anti-angiogenic cancer therapy.
language: eng
source:
identifier: ISSN: 0142-9612 ; DOI: 10.1016/j.biomaterials.2013.10.074
fulltext: fulltext
issn:
  • 01429612
  • 0142-9612
url: Link


@attributes
ID298532941
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordidS0142-9612(13)01330-6
sourceidsciversesciencedirect_elsevier
recordidTN_sciversesciencedirect_elsevierS0142-9612(13)01330-6
sourcesystemOther
pqid1477554172
galeid353944332
display
typearticle
titleSimultaneous delivery of doxorubicin and curcumin encapsulated in liposomes of pegylated RGDK-lipopeptide to tumor vasculature
creatorBarui, Sugata ; Saha, Soumen ; Mondal, Goutam ; Haseena, Shaik ; Chaudhuri, Arabinda
ispartofBiomaterials, February 2014, Vol.35(5), pp.1643-1656
identifierISSN: 0142-9612 ; DOI: 10.1016/j.biomaterials.2013.10.074
subjectPegylated Rgdk-Lipopeptide ; Curcumin–Doxorubicin Synergy ; Tumor Growth Inhibition ; Targeting Tumor Vasculature ; Anti-Angiogenic Chemotherapy
descriptionCurcumin, because of its distinguishing ability to inhibit activation of transcription factor linked to chemoresistance and drug transporters, is now being co-administered with various potent anti-cancer drugs. In the present study, we report on such potentiating capabilities of curcumin in anti-angiogenic cancer therapy. With a view to simultaneously deliver curcumin and doxorubicin to tumor vasculature in anti-angiogenic cancer therapy, herein we report on the design & synthesis of a tumor vasculature targeting pegylated RGDK-lipopeptide. We show that curcumin & doxorubicin co-encapsulated within the liposomes of the presently described pegylated RGDK-lipopeptide exhibit synergism in inhibiting proliferation, invasion and migration of both tumor and endothelial cells presumably by inhibiting proliferation and metastasis related genes both at mRNA & protein levels. Pronounced tumor growth inhibition was observed in mice treated with formulations containing both the drugs. Tumor growth inhibition was found to be 2–3 folds less in mice treated with formulations containing only curcumin or only doxorubicin. The presently described liposomal system is expected to find future use for simultaneously delivering potentially any combinations of hydrophilic and hydrophobic potent small molecule cancer therapeutics to tumor vasculature in anti-angiogenic cancer therapy.
languageeng
source
version5
lds50peer_reviewed
links
openurl$$Topenurl_article
backlink$$Uhttp://dx.doi.org/10.1016/j.biomaterials.2013.10.074$$EView_record_in_ScienceDirect
openurlfulltext$$Topenurlfull_article
search
creatorcontrib
0Barui, Sugata
1Saha, Soumen
2Mondal, Goutam
3Haseena, Shaik
4Chaudhuri, Arabinda
titleSimultaneous delivery of doxorubicin and curcumin encapsulated in liposomes of pegylated RGDK-lipopeptide to tumor vasculature
descriptionCurcumin, because of its distinguishing ability to inhibit activation of transcription factor linked to chemoresistance and drug transporters, is now being co-administered with various potent anti-cancer drugs. In the present study, we report on such potentiating capabilities of curcumin in anti-angiogenic cancer therapy. With a view to simultaneously deliver curcumin and doxorubicin to tumor vasculature in anti-angiogenic cancer therapy, herein we report on the design & synthesis of a tumor vasculature targeting pegylated RGDK-lipopeptide. We show that curcumin & doxorubicin co-encapsulated within the liposomes of the presently described pegylated RGDK-lipopeptide exhibit synergism in inhibiting proliferation, invasion and migration of both tumor and endothelial cells presumably by inhibiting proliferation and metastasis related genes both at mRNA & protein levels. Pronounced tumor growth inhibition was observed in mice treated with formulations containing both the drugs. Tumor growth inhibition was found to be 2–3 folds less in mice treated with formulations containing only curcumin or only doxorubicin. The presently described liposomal system is expected to find future use for simultaneously delivering potentially any combinations of hydrophilic and hydrophobic potent small molecule cancer therapeutics to tumor vasculature in anti-angiogenic cancer therapy.
subject
0Pegylated Rgdk-Lipopeptide
1Curcumin–Doxorubicin Synergy
2Tumor Growth Inhibition
3Targeting Tumor Vasculature
4Anti-Angiogenic Chemotherapy
general
0English
1Elsevier Ltd
210.1016/j.biomaterials.2013.10.074
3ScienceDirect (Elsevier B.V.)
4ScienceDirect Journals (Elsevier)
sourceidsciversesciencedirect_elsevier
recordidsciversesciencedirect_elsevierS0142-9612(13)01330-6
issn
001429612
10142-9612
rsrctypearticle
creationdate2014
addtitleBiomaterials
searchscope
0sciversesciencedirect_elsevier
1elsevier_sciencedirect
scope
0sciversesciencedirect_elsevier
1elsevier_sciencedirect
startdate20140201
enddate20140231
citationpf 1643 pt 1656 vol 35 issue 5
lsr30VSR-Enriched:[pqid, galeid, eissn]
sort
titleSimultaneous delivery of doxorubicin and curcumin encapsulated in liposomes of pegylated RGDK-lipopeptide to tumor vasculature
authorBarui, Sugata ; Saha, Soumen ; Mondal, Goutam ; Haseena, Shaik ; Chaudhuri, Arabinda
creationdate20140200
lso0120140200
facets
frbrgroupid2858988851235784459
frbrtype5
languageeng
creationdate2014
topic
0Pegylated Rgdk-Lipopeptide
1Curcumin–Doxorubicin Synergy
2Tumor Growth Inhibition
3Targeting Tumor Vasculature
4Anti-Angiogenic Chemotherapy
collectionScienceDirect Journals (Elsevier)
prefilterarticles
rsrctypearticles
creatorcontrib
0Barui, Sugata
1Saha, Soumen
2Mondal, Goutam
3Haseena, Shaik
4Chaudhuri, Arabinda
jtitleBiomaterials
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Barui
1Saha
2Mondal
3Haseena
4Chaudhuri
aufirstSugata
au
0Barui, Sugata
1Saha, Soumen
2Mondal, Goutam
3Haseena, Shaik
4Chaudhuri, Arabinda
atitleSimultaneous delivery of doxorubicin and curcumin encapsulated in liposomes of pegylated RGDK-lipopeptide to tumor vasculature
jtitleBiomaterials
risdate201402
volume35
issue5
spage1643
epage1656
pages1643-1656
issn0142-9612
formatjournal
genrearticle
ristypeJOUR
abstractCurcumin, because of its distinguishing ability to inhibit activation of transcription factor linked to chemoresistance and drug transporters, is now being co-administered with various potent anti-cancer drugs. In the present study, we report on such potentiating capabilities of curcumin in anti-angiogenic cancer therapy. With a view to simultaneously deliver curcumin and doxorubicin to tumor vasculature in anti-angiogenic cancer therapy, herein we report on the design & synthesis of a tumor vasculature targeting pegylated RGDK-lipopeptide. We show that curcumin & doxorubicin co-encapsulated within the liposomes of the presently described pegylated RGDK-lipopeptide exhibit synergism in inhibiting proliferation, invasion and migration of both tumor and endothelial cells presumably by inhibiting proliferation and metastasis related genes both at mRNA & protein levels. Pronounced tumor growth inhibition was observed in mice treated with formulations containing both the drugs. Tumor growth inhibition was found to be 2–3 folds less in mice treated with formulations containing only curcumin or only doxorubicin. The presently described liposomal system is expected to find future use for simultaneously delivering potentially any combinations of hydrophilic and hydrophobic potent small molecule cancer therapeutics to tumor vasculature in anti-angiogenic cancer therapy.
pubElsevier Ltd
doi10.1016/j.biomaterials.2013.10.074
eissn18785905
date2014-02